- Global Pharma News & Resources

BD to Showcase its Commitment to Drug Delivery and Packaging Innovation at CPhI Worldwide 2022 Conference

BD to Showcase its Commitment to Drug Delivery and Packaging Innovation at CPhI Worldwide 2022 Conference

FRANKLIN LAKES, N.J., October 20, 2022 / B3C newswire / -- BD (Becton, Dickinson and Company), a leading global medical technology company, is pleased to sponsor CPhI Worldwide Conference – building on its decades of expertise in partnering with the biopharmaceutical industry to advance drug delivery excellence.

CPhI WW will be held in Frankfurt, Germany from November 1 to November 3, 2022. The conference will focus on product sustainability and innovation across the pharmaceutical supply chain. BD will serve as a Platinum Sponsor and participate in talks throughout the conference, including:

  • “Container Closure Integrity Testing - Deterministic Methods” on November 1 at 11:30 by Kayla Kaspar, Technology Development Manager at ZebraSci
  • “The Next Generation Vaccine Syringe - BD Effivax™ Glass Prefillable Syringe” on November 1 at 15:00 Vincent Hérin, Associate Director, R&D Program Management
  • “Clinical Evaluation of an Investigational 5ml Wearable Injector” on November 1 at 15:30 by Natasha Bolick, Associate Director, BD Technologies & Innovation

At the booth, BD will show our wide range of services and solutions to help meet your combination product development needs.  BD experts will be on site to discuss a variety of topics related to the next generation of drug delivery, including:

  • BD Effivax™ Glass Prefillable Syringe – a next-generation glass prefillable syringe that has been designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing. BD Effivax™ Glass Prefillable Syringe sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, contamination and integrity.1
  • BD Evolve™ On-body Injector* – a programmable, variable dose on-body injector. It offers pharmaceutical companies a wearable solution that enables new delivery formats in alternate settings. It is designed to enable subcutaneous administration of up to 3 mL of medication, with up to three days of wear.
  • A complete range of services across BD Pharmaceutical Services and Solutions and ZebraSci combination product services to help you achieve your combination product development goals.
  • An Innovation Corner featuring early concept new product innovations.

BD looks forward to the on-site collaboration with biopharmaceutical partners, as we continue to prioritize drug delivery innovation.

Editor Details

Last Updated: 20-Oct-2022